Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
Radiology|February 2, 2018
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-FluoroglutamineMark P S Dunphy, James J Harding, Sriram Venneti, et al.Journal of the National Cancer Institute|March 23, 2021
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and OutcomesAnna M Varghese, Isha Singh, Rituraj Singh, et al.Cancer|January 17, 2018
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinomaEileen M O'Reilly, Jonathan W Lee, Maeve A Lowery, et al.Cancer|June 24, 2020
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaCaitlin A McIntyre, Sharon A Lawrence, Allison L Richards, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 9, 2018
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancerSebastian Mondaca, Matthew Margolis, Francisco Sanchez-Vega, et al.The Oncologist|October 2, 2019
Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric CancerRyan H Moy, Gustavo Dos Santos Fernandes, Philip Jonsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel AdenocarcinomaAlicia Latham, Jinru Shia, Zalak Patel, et al.JAMA Network Open|July 12, 2021
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric CancerGeoffrey Y Ku, Yelena Kemel, Steve B Maron, et al.Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.Pageof 9